IBT B Stock Overview
A clinical stage pharmaceutical company, develops drugs to prevent serious neonatal diseases affecting premature infants in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Infant Bacterial Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 38.20 |
| 52 Week High | SEK 135.00 |
| 52 Week Low | SEK 21.70 |
| Beta | 1.04 |
| 11 Month Change | 4.37% |
| 3 Month Change | -63.62% |
| 1 Year Change | -58.57% |
| 33 Year Change | -43.32% |
| 5 Year Change | -73.94% |
| Change since IPO | -64.13% |
Recent News & Updates
Recent updates
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
Aug 02
Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment
May 02Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans
Apr 03Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation
Sep 16We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
May 11We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate
Sep 23We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely
Apr 07We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
Dec 15We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
Aug 25We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate
May 06Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)
Feb 07Shareholder Returns
| IBT B | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 4.1% | 0.9% | -0.2% |
| 1Y | -58.6% | 9.3% | 11.8% |
Return vs Industry: IBT B underperformed the Swedish Pharmaceuticals industry which returned 9.3% over the past year.
Return vs Market: IBT B underperformed the Swedish Market which returned 11.8% over the past year.
Price Volatility
| IBT B volatility | |
|---|---|
| IBT B Average Weekly Movement | 19.8% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: IBT B's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: IBT B's weekly volatility has increased from 12% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 10 | Staffan Stromberg | www.ibtherapeutics.com |
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies `to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants.
Infant Bacterial Therapeutics AB (publ) Fundamentals Summary
| IBT B fundamental statistics | |
|---|---|
| Market cap | SEK 514.61m |
| Earnings (TTM) | -SEK 144.03m |
| Revenue (TTM) | SEK 5.00k |
Over9,999x
P/S Ratio-3.6x
P/E RatioIs IBT B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBT B income statement (TTM) | |
|---|---|
| Revenue | SEK 5.00k |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 5.00k |
| Other Expenses | SEK 144.04m |
| Earnings | -SEK 144.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -10.69 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,880,640.00% |
| Debt/Equity Ratio | 0% |
How did IBT B perform over the long term?
See historical performance and comparison